Beata Chertok’s research expertise is in engineering advanced biomaterials at the nanometer and micrometer scales for targeted, image-guided and personalized drug delivery. Professor Chertok received her B.S. in Pharmacy from the Hebrew University of Jerusalem (Israel), and M.S. in Biomedical Engineering from the Technion (Israel Institute of Technology). Her PhD work at the University of Michigan investigated iron-oxide nanoparticles and laid the foundation for their utilization in MRI-monitored and magnetically- targeted delivery of protein therapeutics to brain tumors. As a NIH/NIBIB Postdoctoral Fellow at the Massachusetts Institute of Technology, Dr. Chertok studied ultrasound-responsive biomaterials and developed novel multifunctional micro-platform for targeted, magneto-acoustic delivery of genetic therapeutics to tumors with ultrasound guidance. Dr. Chertok is a recipient of multiple research awards including the MIT Cancer Center for Nanotechnology Excellence Award and the National Institute of Biomedical Imaging and Bioengineering (NIH/NIBIB) National Research Service Award for Postdoctoral Fellows.  Prior to obtaining her Ph.D., Dr. Chertok served as a pharmacy practitioner and as a formulation scientist at Taro Pharmaceuticals. Dr. Chertok joined the University of Michigan as an Assistant Professor of Pharmaceutical Sciences and Biomedical Engineering in the Fall 2013. Research in Professor Chertok’s laboratory lies at the interface of pharmaceutical sciences and biomedical engineering and is focused on development of the next generation “remote” and image-guided drug platforms for cancer therapy.


St. Baldrick's Scholar Award, 2015

The National Institute of Biomedical Imaging and Bioengineering (NIH/NIBIB) National Research Service Award for Individual Postdoctoral Fellows, Grant # 1F32EB015835-01, 2012

The MIT Cancer Center for Nanotechnology Excellence Award, 2010

Rackham Graduate School Pre-doctoral Fellowship (top 1% of all graduate students, awarded in support of unusually creative, ambitious, and risk-taking dissertation research), University of Michigan, 2007

Elizabeth Broomfield Award for Outstanding International Graduate Students in Pharmaceutical Sciences, 2005

Dean’s fellowship for recruiting outstanding candidates to the U-M Pharmaceutical Sciences Program, 2003


Dr. Chertok’s research program aims to engineer ‘remote control’ therapies. Drugs that traffic through the human body often settle in undesired locations, thereby causing side effects. What if drug trafficking could be remote-controlled? One click on the remote – and the blood-stream injected drug is activated selectively in a diseased region of the brain. Another click – and the patient’s own immune cells are provoked to attack cancerous growth. Toward realization of these ideas, the Chertok laboratory for    ‘Remote and Image-Guided Therapeutics’ focuses on design of remotely-actuated biomaterials at the nanometer and micrometer scales. These materials are engineered to encapsulate therapeutics, mediate spatially-defined drug and gene delivery and stimulate target cells in response to remote, tissue-penetrant magnetic or acoustic signals. In order to manipulate the trafficking of drugs in the body, it is important to monitor their distribution. Toward this goal, the lab designs drug carriers that are visible to clinical imaging modalities such as MRI and ultrasound and develops quantitative imaging techniques. Dr. Chertok’s research lies at the interface of pharmaceutical sciences and biomedical engineering and borrows expertise from the fields of biomaterials engineering, bio-actuation and medical imaging as well as drug/gene delivery, nano-micro encapsulation and pharmacokinetics.

Feature Story
Dr. Beata Chertok Gains Acclaim and Grant for Research Work

Dr. Chertok’s work was recognized with the Fay Frank 2015 Seed Grant from the Brain Research Foundation (BRF). Dr. Chertok was selected to receive this award as one of only 11 scientists from 29 US institutions invited by the foundation. The objective of the BRF Seed Grant Program is to support new and innovative projects, especially those of junior faculty who are working in new research directions in the field of neuroscience. The funding will support Dr. Chertok’s mission to develop tiny devices the size of blood cells that can be injected into the blood stream and non-invasively activated to modulate immune responses in the brain.

Research Interests

  • Targeted and image-monitored drug delivery and stimuli-responsive, nano-/micro-scale biomaterials for cancer therapy

  • Areas include biomaterials, drug and gene delivery, nanotechnology and microtechnology, bio-actuation, theranostics, image-guided therapy, pharmacokinetics

Selected Publications

  • Beata Chertok, Robert Langer, and Daniel G. Anderson. Spatial Control of Gene Expression by Nanocarriers Using Heparin Masking and Ultrasound-Targeted Microbubble Destruction. ACS Nano. 10(8), pp.7267-7278, 2016

  • Beata Chertok, Matthew Webber, Marc Succi, Robert Langer. Drug Delivery Interfaces in the 21st Century: From Science Fiction Ideas to Viable Technologies. Molecular Pharmaceutics. 10(10), pp. 3531-354, 2013

  • Beata Chertok, Allan E. David, Victor C. Yang. Brain Tumor Targeting of Magnetic Nanoparticles for Potential Drug Delivery: Effect of Administration Route and Magnetic Field Topography. Journal of Controlled Release, 155(3), pp. 393-9, 2011

  • Beata Chertok, Allan E. David, Victor C. Yang. PEI-Modified Iron Oxide Nanoparticles for Brain Tumor Drug Delivery Using Magnetic Targeting and Intra-Carotid Administration. Biomaterials 31, pp. 6317-6324, 2010

  • Beata Chertok, Bradford A. Moffat , Allan E. David , Faquan Yu, Christian Bergemann, Brian D. Ross, Victor C. Yang. Iron Oxide Nanoparticles as a Drug Delivery Vehicle for MRI Monitored Magnetic Targeting of Brain Tumors. Biomaterials, 29(4), pp. 487-496, 2008 [cited over 250 times]